Trial Profile
A Randomized Phase I/II Study Of Sorafenib In Combination With High Dose Chemoradiation In Patients With Stage IIIA/B Non-small Cell Lung Cancer (NSCLC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jan 2019 Status changed to withdrawn prior to enrolment.
- 08 Jan 2019 Status changed to withdrawn prior to enrolment.
- 19 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.